Nanovaccine derived from pre-chemotherapy tumors combats multiple tumors in mice
A research team led by Prof. Nie Guangjun from the National Center for Nanoscience and Technology (NCNST) of the Chinese Academy of Sciences (CAS) and collaborators have demonstrated a tumor membrane antigens-based nanovaccine derived from liposomal doxorubicin treated tumor tissues, which is efficacious in inducing a potent immunological defense against tumors. The study is published online in Cell Reports Medicine.
